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Abstract
Hepatitis B virus-infected patients secrete enormous quantities (50–300 g/ml) of hepatitis B surface antigen (HBsAg) in their serum.
One hypothesis for this synthetic effort is that these lipoprotein particles serve to adsorb neutralizing antisurface antibodies. We have shown
that insulin suppresses the expression of HBsAg in human hepatoma cell Hep3B cells. We further studied the signaling pathway of insulin
on the inhibition of HBsAg. Using a fungal metabolite, lovastatin, to block the p21Ras signaling pathway of insulin, we found that lovastatin
inhibited the secretion of HBsAg into culture medium in Hep3B cells; however, the involvement of p21Ras-MAPKs was excluded in this
effect. The cholesterol depletion from the membrane, leading to the destabilization of rafts, was the mechanism for the lovastatin inhibition
of HBsAg secretion. However, lovastatin has no effect on the secretion of infectious viral Dane particles. Herein, we show for the first time
that cholesterol is required for HBsAg secretion.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Despite the development of the first successful recombi-
nant vaccine for a human infectious disease, over 250 mil-
lion people worldwide are persistently infected with hepa-
titis B virus (HBV), and of these a significant minority
develop severe pathologic consequences, including chronic
hepatic insufficiency, cirrhosis, and hepatocellular carci-
noma. Hepatitis B virus is unusual among animal viruses in
that infected cells produce multiple types of virus-related
particles. Electron microscopy of partially purified HBV
from human serum shows three types of viral particles:
43-nm double-shelled particles, named “Dane” particles,
that represent the infectious virion; 20-nm spheres, usually
present in 103- to 106-fold excess over virions; and filaments
of 20-nm diameter and variable lengths (Dane et al., 1970;
Robinson and Lutwick, 1976). All three structures comprise
a common glycoprotein antigen (hepatitis B surface antigen,
HBsAg) on their exterior. Dane particles contain HBsAg
only on their outer shell. The spheres and filaments are
composed exclusively of this antigen and associated host-
derived lipids. Lacking viral nucleic acid, the subviral li-
poprotein particles are noninfectious; nevertheless, the
enormous quantities of HBsAg (50–300 g/ml of serum)
are a regular feature of infection. The reasons for this
synthetic effort are still not clear, but one possibility is that
these “dummy” particles serve to adsorb neutralizing anti-
surface antibodies during the progression of infection. Un-
like most viral envelope glycoproteins, HBsAg is indepen-
dently secreted from infected cells as subviral lipoprotein
particles. Notably, all the viral information required for
particle formation and export resides within the S coding
region: cultured cell lines transfected with S gene alone can
assemble and secrete HBsAg particles in the absence of
other viral proteins (Dubois et al., 1980; Liu et al., 1982). In
the biogenesis of HBsAg particle, HBsAg is initially syn-
thesized as a transmembrane protein in the endocytoplasmic
reticulum (ER) membrane. This material then undergoes a
conformational change in the lipid bilayer in a way as to
make it resistant to protease. At this stage, the antigen is still
integrally associated with the bilayer. In the third step, the
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assembled HBsAg complexes completely transferred into
the ER lumen. Once formed the complex is rapidly exported
to the cell exterior via the normal vesicular pathways (Si-
mon et al., 1988). The HBsAg is a protein of 24 kDa that is
present in both unglycosylated (p24s) and glycosylated
(gp27s) forms (Peterson, 1981). These polypeptides are se-
creted in the form of lipoprotein particles containing ap-
proximately 100–200 polypeptide monomers per particle
and a host-derived lipid that comprises around 25% of the
particle mass. The lipid composition of HBsAg is relatively
invariant and consists of phosphatidylcholine (60%), cho-
lesteryl ester (14%), cholesterol (15%), and triglycer-
ides (3%) (Gavilanes et al., 1982). The biological signif-
icance of different lipid components in the formation of
HBsAg particles has not yet been characterized.
We have been studying the gene expression and secre-
tion of HBsAg by insulin and TPA (12-O-tetradecanoyl
phorbol-13-acetate) using a human hepatoma cell line,
Hep3B (Lin et al., 1995). This cell line contains an inte-
grated HBV genome, which constantly expresses and se-
cretes HBsAg into culture media but no other viral proteins
or infectious particles (Knowles et al., 1980). To further
understand the signaling pathway of insulin on HBsAg, we
used lovastatin to inhibit the membrane anchorage of
p21Ras. Lovastatin is a competitive inhibitor of 3-hydroxy-
3-methylglutary-CoA (HMG-CoA) reductase involved in
the de novo synthesis of mevalonate and cholesterol. Me-
valonate is the precursor of several isoprenoids, which are
involved in the isoprenylation of several membrane-an-
chored proteins, i.e., p21Ras and lamins. Lovastatin has
been shown to block the membrane anchorage of p21Ras
and it activity (Leonard et al., 1990). To our surprise, we
found that lovastatin inhibited the secretion of HBsAg, but
the Ras pathway was not involved in this inhibition. This
finding led us to study the importance of cholesterol in
HBsAg secretion, and we showed that this inhibition was
due to its cholesterol-lowering activity. Depletion of cho-
lesterol from the membrane, leading to the destabilization of
rafts (Nguyen and Taub, 2002), inhibits HBsAg secretion.
Furthermore, the GPI-anchored signaling that requires cho-
lesterol was not involved in this inhibition. Our results show
for the first time that cholesterol is important for the secre-
tion of HBsAg.
Results
Lovastatin inhibits the production of HBsAg by Hep3B
cells
Hep3B cells were treated with different concentrations of
lovastatin for 48 h in serum-free medium after serum star-
vation. The culture medium was then harvested and the
amounts of HBsAg were measured by ELISA. As shown in
Fig. 1A, lovastatin treatment inhibited HBsAg production
by 60% and this inhibition was in a dose-dependent manner.
The proliferation of Hep3B cells during lovastatin treatment
was also evaluated. As seen in Fig. 1A, lovastatin had no
inhibitory effect on the proliferation of Hep3B cells during
48-h treatment. The secretion of albumin was not affected,
ruling out a general effect of lovastatin on vesicular trans-
port (Fig. 1B). To verify whether the inhibitory effect of
lovastatin on HBsAg production was not restricted to a
specific cell line, an other hepatoma cell line expressing
HBsAg was employed for the evaluation. An HBV genome
has been transfected into a human hepatoma cell line HepG2
and a stable clone was selected, which resulted in HepG2/A2
cells (Chen et al., 1995). As seen in Fig. 1C, lovastatin
inhibited the secretion of HBsAg in culture medium of
HepG2/A2 cells in a dose-dependent manner and lovastatin
treatment had no effect on cell proliferation. This cell line
expresses all viral proteins, including HBeAg, which is
secreted independently from the three viral particles. Secre-
tion of HBeAg was not affected by lovastatin treatment
(Fig. 1D). These results imply that lovastatin specifically
inhibits the secretion of HBsAg into culture medium and
this inhibitory effect is not restricted to Hep3B cells.
Mevalonate reverses the inhibition of HBsAg secretion by
lovastatin
To evaluate whether the downstream product of HMG-
CoA reductase can reverse the inhibitory effect of lova-
statin, mevalonate was added during the lovastatin treat-
ment. As seen in Fig. 2, both 5 and 10 mM of mevalonate
reversed the inhibition of HBsAg secretion by lovastatin.
The inhibitory effect of 1 M lovastatin was completely
blocked by 10 mM of mevalonate.
Inhibition of HBsAg is not on the HBsAg gene promoter
and mRNA level
We have shown that insulin and TPA inhibit the produc-
tion of HBsAg on the mRNA level (Lin et al., 1995) and
down-regulates the activity of the proximal SPII promoter
of HBsAg (data not shown). The inhibition of lovastatin
upon HBsAg promoter was evaluated. The SPII promoter of
HBsAg gene (Chang et al., 1989) was inserted prior to a
firefly luciferase reporter gene. This construct was then
transfected into SV40 T antigen-transformed human em-
bryo kidney 293T cells or Hep3B cells. As shown in Fig. 3A
and B, lovastatin treatment had no effect on the luciferase
activity in 293T or Hep3B cells, whereas it inhibited the
secretion of endogenous HBsAg of Hep3B cells. This result
suggests that the inhibitory effect of lovastatin on HBsAg is
not on the promoter level. To verify whether the inhibitory
effect of lovastatin is on the level of steady-state mRNA,
Hep3B cells were treated with different concentrations of
lovastatin and mRNA was extracted. As seen in Fig. 3C,
lovastatin had no effect on the expression of 2.1-kb mRNA,
whereas TPA suppressed the HBsAg mRNA expression.
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Inhibition of HBsAg is not on the translational level
To further clarify whether the effect of lovastatin on
HBsAg is on the protein translation. Hep3B cells were
pulse-labeled with 35S-labeled methionine for 1 or 2 h and
HBsAg proteins were immunoprecipitated with anti-HBsAg
antiserum. As shown in Fig. 3D, 48-h treatment of lova-
statin had no effect on the translation of HBsAg.
Cholesterol diminishes the inhibitory effect of lovastatin
To verify whether the inhibition of HBsAg production by
lovastatin was a result of the inhibition of cholesterol de
novo synthesis, cholesterol was added during the lovastatin
treatment. Hep3B cells were treated with different concen-
trations of cholesterol and lovastatin. The inhibitory effect
of lovastatin upon HBsAg was attenuated, whereas increas-
ing the concentrations of cholesterol (Fig. 4A). To further
prove the inhibitory effect of lovastatin to be due to cho-
lesterol lowering, filipin III was also tested for the inhibition
of HBsAg. As seen in Fig. 4B, lovastatin or filipin III
inhibited the HBsAg production and the addition of filipin
III further enhanced the effect of lovastatin. These data
Fig. 1. Effects of lovastatin upon the production of HBsAg and cell proliferation (A) and albumin secretion (B) in Hep3B cells. Effects of lovastatin upon
the production of HBsAg and cell proliferation (C) and HbeAg secretion (D) in HepG2/A2 cells. Cells were seeded at a density of 105 cells/well in 24-well
plates. They were treated with different concentrations of lovastatin for 48 h after serum starvation. Culture medium was then collected. The amounts of
HBsAg were measured using ELISA. Cell numbers were counted using hemocytometry. The percentages of HBsAg production and cell number from
different treatment were expressed in comparison with control cells, which was considered as 100% in both HBsAg production and cell proliferation.
Fig. 2. Effect of mevalonate on lovastatin suppressed HBsAg secretion.
Hep3B cells were treated with various concentrations of lovastatin in the
absence or presence of 5 or 10 mM mevalonate for 48 h after serum
starvation. The amounts of HBsAg in culture medium were determined by
ELISA. Percentages of HBsAg production from different treatment were
expressed in comparison with the untreated control cells, which were
considered as 100% in HBsAg production. LOV, lovastatin-treated cells;
Mev, mevalonate-treated cells.
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show that lowering the cellular cholesterol level is sufficient
to reduce the secretion of HBsAg.
HBsAg inhibition is not due to the blockage of
Ras-MAPKs pathway by lovastatin treatment
Lovastatin has been shown to block the membrane an-
chorage and activity of small G protein p21Ras due to its
inhibition upon the de novo synthesis of farnesyl pyrophos-
phate (Leonard et al., 1990). The membrane/cytosolic dis-
tribution of p21 Ras was investigated after lovastatin treat-
ment. As shown in Fig. 5A, 5 M of lovastatin treatment for
48 h reduced the membrane anchorage of Ras proteins to an
undetectable level. To further clarify whether the inhibition
of HBsAg was due to the blockage of Ras-MAPKs (mito-
gen-activated protein kinases) pathway, a MEK-MAPKs
inhibitor, U0126 (Favata et al., 1998), was tested. HepG2/A2
cells were treated with different concentrations of U0126
for 48 h and this treatment did not inhibit the secretion of
HBsAg into culture medium (Fig. 5B). These results show
that the inhibition of HBsAg by lovastatin was not ascribed
to the blockage of Ras-MAPKs pathway.
GPI-anchored proteins are not involved in the inhibition
of HBsAg secretion by lovastatin
It has been shown that lovastatin inhibits the signal
transduction via glocosyl phosphatidylinositol-(GPI) an-
chored proteins in T cells by lowering cellular cholesterol
(Stulnig et al., 1997). A GPI biogenesis inhibitor (Lisanti et
al., 1991), mannosamine was used to evaluate the possibil-
ity that HBsAg secretion requires the involvement of GPI-
Fig. 3. Lovastatin effect on HBsAg SPII promoter or mRNA level in 293T (A) or Hep3B cells (B and C). (A) 293T cells were cultured in 6-well plates. They
were transfected with different amounts of SPII-luciferase DNA in the presence of Renilla luciferase as described under Materials and Methods. Transfected
cells were then treated with different concentrations of lovastatin in serum-free DMEM for 48 h. Control cells were expressed as 100% in luciferase activity.
(B) Hep3B cells were transfected with SPII-luciferase as described under “Experimental procedure”. They were then treated with/without 5 M lovastatin
for 48 h after serum starvation. The culture medium was collected for the determination of HBsAg secretion. Luciferase activity was analyzed using a dual
luciferase assay kit. Control cells were expressed as 100% in both luciferase activity and HBsAg secretion. (C) Hep3B cells were treated with different
concentrations of lovastatin or 100 ng/ml TPA for 48 h after serum starvation. Total RNA was extracted and analyzed as described under Materials and
methods. G3PDH gene was probed as an internal control. (D) Lovastatin had no effect on the translational level. Hep3B cells were pulse labeled with
[35S]methionine for 1 or 2 h after 48 h of treatment of 2.5 M lovastatin and HBsAg proteins were immunoprecipitated with anti-HBsAg antiserum. LOV,
lovastatin-treated cells.
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anchored proteins. HepG2/A2 cells were treated with differ-
ent concentrations of mannosamine for 48 h, the amounts of
HBsAg in the culture medium was then measured. As seen
in Fig. 6, the mannosamine treatment had no effect on the
secretion of HBsAg. This implies that lovastatin inhibited
HBsAg secretion by lowering cellular cholesterol was not
through the blockage of signal transduction via GPI-an-
chored proteins.
Dane particles production is not decreased by lovastatin
treatment
To verify whether the lovastatin treatment would affect
the release of infectious particles, viral DNA was measured
by quantitative PCR from the supernatant of HepG2.2.15
cells (Sells et al., 1987). This cell line has been shown to
produce fair amounts of Dane particles. Lovastatin treat-
ment induced a drop of 50% in HBsAg secretion in
HepG2.2.15, whereas it had no effect on the release of
infectious viral particles (Fig. 7).
Fig. 4. (A) Effect of cholesterol on lovastatin suppressed HBsAg secretion.
Hep3B cells were treated with various concentrations of lovastatin in the
absence or presence of different concentrations of cholesterol for 48 h after
serum starvation. The amounts of HBsAg in culture medium were then
determined by ELISA. Untreated control cells were expressed as 100% in
HBsAg secretion. LOV, lovastatin-treated cells; CHO, cholesterol-treated
cells. (B) Filipin III enhanced the inhibitory effect of lovastatin upon
HBsAg secretion. Hep3B cells were treated with lovastatin or filipin III or
both for 48 h after serum starvation. The secretion of HBsAg in culture
medium was analyzed by ELISA. Untreated control cells were considered
as 100% in HBsAg production. SF, control cells; LOV, lovastatin-treated
cells.
Fig. 5. (A) Inhibition of p21Ras membrane anchorage by lovastatin. (B)
Effect of U0126 on HBsAg secretion. (A) Hep3B cells were treated with
lovastatin for 32 hr and 35S-labeled methionine labeled for 16 h after serum
starvation. The cellular distribution of p21Ras was then detected as de-
scribed under Materials and Methods. (B) HepG2/A2 cells were treated
with either lovastatin or U0126 for 48 h after serum starvation. The
amounts of HBsAg in culture medium were then determined by ELISA.
Control cells were expressed as 100% in HBsAg secretion.
Fig. 6. Mannosamine had no effect on HBsAg production in HepG2/A2
cells. Cells were treated with either lovastatin or mannosamine for 48 h
after serum starvation. The culture medium was collected and the amounts
of HBsAg were measured by ELISA. Percentages of HBsAg were ex-
pressed from different treatment in comparison with the control cells,
which were considered as 100% in HBsAg secretion. LOV, lovastatin-
treated cells; Mann, mannosamine-treated cells.
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Discussion
Lipid microdomains, including both caveolae and related
structures (Anderson, 1993; Simons and Ikonen, 1997)
called rafts, are currently intensively investigated. In addi-
tion to playing a role in signal transduction of the host cell,
lipid rafts serve as entry and exit sites for microbial patho-
gens and toxins, such as measles virus and cholera toxin (Lu
and Kielian, 2000; Shogomori and Futerman, 2001). A
number of reports have shown that lipid rafts are important
at various stage of HIV-1 replication cycle (Manes et al.,
2000; Campbell et al., 2001). In these microdomains rich in
cholesterol and sphingolipids, depletion of cholesterol is
sufficient to block the function of these domains in signal
transduction and viral assembly. The involvement of cho-
lesterol in the signal transduction of glycosyl phophatidyli-
nositol- (GPI) anchored proteins has also been shown in
several cell types. GPI-anchored proteins are linked to the
plasma membrane by a phospholipid moiety residing in the
outer leaflet of the lipid bilayer (Englund, 1993). GPI an-
choring has been shown to be important for the intracellular
signaling capacity of several proteins especially in lympho-
cytes (Brown, 1993). Recently, the requirement of choles-
terol for the assembly of some enveloped viruses has been
demonstrated in measles virus and Semliki forest virus (Lu
and Kielian, 2000; Vincent et al., 2000). Furthermore, the
depletion of cholesterol seems to affect the infections of
African swine fever virus (ASFV) and human immunode-
ficiency virus-1 (HIV-1) (Bernardes et al., 1998; Liao et al.,
2001). It has been shown that depletion of cellular choles-
terol by -cyclodextrin renders primary cells and cell lines
highly resistant to HIV-1-mediated syncytium formation
and to infection by both X4 and R5 viruses (Liao et al.,
2001; Nguyen and Taub, 2002). In Jurkat T cells, lowering
cholesterol by different inhibitors suppresses calcium sig-
naling via GPI-anchored CD59 and CD48 (Stulnig et al.,
1997).
In this study, we demonstrated that lovastatin treatment
inhibits the production of HBsAg into culture medium.
From the luciferase assay and the Northern and Western
blots (Fig. 3), we conclude that the effect of lovastatin upon
HBsAg is not on the transcriptional or translational level.
The precursor of cholesterol, mevalonate, and cholesterol
themselves are able to reverse the inhibition by lovastatin.
These results suggest that cholesterol plays an important
role in HBV envelope assembly. MAPK/MEK inhibitor-
U0126 was employed (Fig. 4) to exclude the possibility that
lovastatin treatment blocks the Ras-MAPK pathway, which
has been shown to localize in the caveolae (Liu et al., 1996;
Mineo et al., 1996) and this localization might be involved
in the regulation of virus budding pathway. Inhibition of
HBsAg by filipin III provides an other evidence that low-
ering cholesterol is sufficient to reduce HBsAg secretion.
Combination of lovastatin and filipin III further enhances
the inhibitory effect. This may come from a residual activity
of HMG-CoA reductase after lovastatin treatment, which
still allows the partial synthesis of cholesterol. The involve-
ment of GPI-anchored proteins signaling was also excluded
by the fact that mannosamine treatment has no effect on the
secretion of HBsAg. It has been shown that lovastatin in-
duces cell cycle arrest in certain cells at G1 (Soma et al.,
1992). In Hep3B and HepG2 cells, lovastatin treatment does
not inhibit cell proliferation (Fig. 1A and C).
Our data show for the first time that depletion of cellular
cholesterol inhibits the secretion of HBsAg particles with-
out affecting the release of Dane particles, suggesting a
different mechanism of viral budding. Even without a direct
effect on infectious particles production, lowering choles-
terol may play an adjuvant role in the treatment of HBV
infection by reducing the enormous amounts of HBsAg
particles that may neutralize antisurface antibodies. In this
respect, lovastatin, with its concentration 100 times higher
in the liver than in the general circulation, may be well
adapted for a treatment of hepatitis B.
Fig. 7. Lovastatin treatment had no effect on infectious particles produc-
tion. (A) HepG2.2.15 cells were treated with different concentrations of
lovastatin for 48 h after serum starvation. The amounts of HBsAg were
measured using ELISA as in Fig. 1A. (B) Viral DNA was prepared from
the culture medium supernatant as described under Materials and methods
and quantified by real-time PCR. Results are expressed as DNA copy
number per milliliter of culture supernatant.
258 Y.-L. Lin et al. / Virology 314 (2003) 253–260
Materials and methods
Cell culture
Human hepatoma Hep3B cells were kindly given by Dr.
B. Knowles (Wista Institute, PA). Both Hep3B, HepG2/A2,
and HepG2.2.15 cells were maintained in Dulbecco’s mod-
ified Eagle medium (DMEM) (Life Technologies) supple-
mented with 10% heat-inactivated fetal calf serum (FCS,
Life Technologies), penicillin/streptomycin (50 units/ml
and 50 g/ml, respectively, Life Technologies), 2 mM glu-
tamine (Life Technologies), and 1X nonessential amino
acids (Life Technologies) in an atmosphere of 5% CO2,
95% air at 37°C. Simian virus (SV40) T antigen-trans-
formed human embryo kidney 293T cells were cultured in
DMEM with 10% FCS, antibiotics, and 1 X glutamax-1 at
37°C. Cells were treated with lovastatin or other chemicals
for 48 h after 24 h of serum starvation. The culture medium
was then collected and the expression of HBsAg, HBeAg,
or albumin was measured using ELISA kits.
Construction and DNA transfection
The pSPII-luc was generated by the insertion of a XbaI/
HindIII fragment from the proximal promoter (SPII) of
HBsAg gene (Chang et al., 1989) to NheI/HindIII of pGL3-
basic vector which contains a firefly luciferase reporter gene
(Promega). In 293T cells, different amounts of pSPII-Luc
were cotransfected with 100 ng of Renilla luciferasae,
pRL-TK (Promega), into 5  105 cells using the calcium
phosphate method (14). In Hep3B cells, transfection was
performed using the Exgen 500 method (Euromedex). In
brief, 5  105 Hep3B cells were seeded in a Six-well plate.
The culture medium was changed to 1 ml of serum-free
DMEM before the transfection. Three micrograms of pSPII-
Luc and 300 ng pRL-TK were incubated with 10 l of
Exgen 500. The DNA mix was then added to the cells after
the incubation at room temperature for 30 min. Culture
medium was changed to serum-free DMEM with/without
lovastatin after overnight transfection. Dual luciferase was
analyzed after 48 h using Dual Luciferase Assay Kit (Pro-
mega).
Analysis of p21Ras localization
Hep3B cells were seeded in a 150-mm plate. After 48 h
of serum starvation, cells were treated with 5 M lovastatin
or kept in serum-free DMEM for 32 h. Culture medium was
changed to methionine-free DMEM. Cells were then la-
beled with 150 mCi/ml 35S-labeled methionine (800–1200
Ci/mmole) for 16 h. In lovastatin-treated cells, 5 M lova-
statin was kept during the labeling period. The labeled cells
were washed with buffer A [20 mM Tris–HCl (pH 7.4), 2
mM EDTA, 0.5 mM EGTA, 0.33 M sucrose, and protease
inhibitors] to remove the radioactivity. Cells were then
harvested and transferred into a Dounce homogenizer. After
40–50 strokes, nuclei were spinned down by centrifugation
at 1,500 rpm for 15 min at 4°C. Supernatant was centrifuged
at 55,000 rpm for 30 min at 4°C and harvested as cytoplasm
fraction. The pellet was dissolved in buffer B [20 mM
Tris–HCl (pH 7.4), 2 mM EDTA, 0.5 mM EGTA, 1%
Triton X-100, and protease inhibitors] and further centri-
fuged at 55,000 rpm for 30 min. Supernatant was collected
as membrane fraction. Ras proteins were immunoprecipi-
tated from both fractions using anti-Ras monoclonal anti-
body (Oncogene Science) at 4°C for 2 h and protein
A–Sepharose for another hour. Ras–Sepharose complex
was washed five times with TEN [10 mM Tris–HCl (pH
8.0), 0.1 mM EDTA, 100 mM NaCl]. The precipitates were
analyzed using 12.5% Sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE). The gel was then
immersed in radioactivity intensifying solution (Autoflour)
for 30 min and autoradiographed.
Pulse labeling of HBsAg proteins
Hep3B cells were seeded in a 100-mm plate. After 48 h
of serum starvation, cells were treated with 5 M lovastatin
or kept in serum-free DMEM for another 48 h. Culture
medium was changed to methionine-free and cystine-free
RPMI medium containning 2% of FCS. Cells were then
labelled with 1 mCi/ml 35S-labeled methionine (800–1200
Ci/mmole) for 1 or 2 h. Cells were then lysed with RIPA
buffer [150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS,
50 mM Tris (pH 8.0)]. HBsAg proteins were immunopre-
cipitated with anti-HBsAg anti-serum (DAKO) and proteins
G- and A-Sepharose (Amersham) and analyzed in a 12.5%
SDS–PAGE. The gel was then fixed in 30% ethanol and
10% acetic acid and autoradiographed for 96 h.
RNA isolation and Northern blot analysis
Total cellular RNA(20 g), extracted by the guanidine
isothiocyanate/cesium chloride method (Chirgwin et al.,
1979) from the control and the treated cells, was subjected
to electrophoresis in a 1.0% agarose/formaldehyde gel and
transferred to nitrocellulose. After hybridization with a mul-
tiprimer-labeled (Amersham) HBsAg probe (Lin et al.,
1995), the blot was washed in a solution containning 0.1X
SSC (1X SSC : 0.15 M sodium chloride, 0.015 M sodium
citrate, pH 7.0), and 0.1% SDS at 55°C for 30 min the blot
was then autoradiographed for 12 h at 70°C with an
intensifying screen (Quanta IV, DuPont).
Quantitative PCR
Culture supernatant was treated with 100 U/ml of RNAse
free-DNAse and 10 mM MgCl2 for 1 h at 37°C. One-tenth
of 10X PK buffer [100 mM Tris (pH 8.0) 5 mM EDTA,
0.01% Triton, 0.001% SDS] and 100 g/ml proteinase K
were added and incubated 3 h at 50°C and 10 min at 95°C.
DNA was ethanol precipitated and resuspended in water.
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DNA was amplified with oligomers GACCACCAAATGC-
CCCTAT and CGAGATTGAGATCTTCTGCGAC at 65°C
in a LightCycler (Roche) with SYBR Green following the
manufacturer’s recommendations. Amplified products were
analyzed on agarose gel and sequenced. Standard curve was
established by analyzing serial dilution of a positive control
plasmid. The PCR cycle at which the amplification signal
entered the exponential range was used to quantify the
DNA. Absence of cellular DNA contamination was verified
by amplification with primers GTGAAGCAAATCG-
CAGCCGCG and TCCCACTGGGCGGCAGCATAGT
specific for the CCR5 gene.
Materials
HBsAg ELISA kit, Hepanstika, is from Organon
Teknika. HBeAg ELISA kit is from Abbott. Albumin
ELISA kit is from Orgentec. Mevalonic acid lactone, cho-
lesterol, filipin III, and mannosamine are from Sigma.
U0126 is from Promega. Lovastatin is from Merck. Both
mevalonate and lovastatin were generated from their respec-
tive lactones by hydrolysis in NaOH.
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